Based on the above, throughout this manuscript the term diabetic cardiomyopathy will be used to designate the cardiac structural and functional abnormalities resulting from hyperglycemia and the relevant metabolic abnormalities (systemic insulin resistance and impaired cardiac insulin metabolic signaling, dyslipidemia) rendering the diabetic myocardium vulnerable to HF development [34,35]. Here, INS is linked to metabolic syndrome.